[TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS]

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune, demyelinating, and neurodegenerative disorder of the central nervous system (CNS).
• Despite available therapies, approximately 30% of patients experience breakthrough disease due to factors like poor adherence, neutralizing antibodies, or high disease activity.
• Teriflunomide, an oral immunomodulatory drug, offers an alternative therapeutic option for managing relapsing-remitting MS.

Purpose of the Study:

• To evaluate the efficacy and safety of teriflunomide in reducing disease activity in multiple sclerosis.
• To compare teriflunomide's effectiveness and patient satisfaction against established therapies like interferon beta-1a/1b.

Main Methods:

• Analysis of data from one Phase II and four Phase III clinical trials (TEMSO, TOWER, TENERE, TOPIC) investigating teriflunomide.
• Placebo-controlled trials assessed relapse rates, disability progression, and time to clinically definitive MS in patients with clinically isolated syndrome (CIS).
• The TENERE study specifically compared teriflunomide 14 mg with subcutaneous interferon beta-alpha (s.c. IFNβ-α) regarding treatment failure, relapse rates, and patient-reported outcomes.

Main Results:

• Teriflunomide 14 mg daily significantly reduced annualized relapse rates by 31.5% and 36.3% in two Phase 3 trials.
• The drug also significantly decreased sustained disability progression by 29.8% and 31.5% in the same studies.
• In the TENERE study, teriflunomide showed comparable efficacy to s.c. IFNβ-α but resulted in significantly higher treatment satisfaction, particularly concerning side-effects and convenience.

Conclusions:

• Teriflunomide is an effective oral treatment for reducing disease activity in relapsing-remitting multiple sclerosis.
• It demonstrates significant benefits in lowering relapse rates and slowing disability progression.
• Teriflunomide offers a favorable alternative to injectable therapies, improving patient satisfaction with treatment convenience and tolerability.